# Aurinia Pharmaceuticals Inc.: financial statements, quarterly

AUPH · Nasdaq · CIK 1600620 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/auph.md) · [Financials](/companies/auph/financials.md) · [Filings](/companies/auph/filings.md) · [Insiders](/companies/auph/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/auph/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [54.5](/filings/0001600620-25-000011.md) | [45.1](/filings/0001600620-25-000011.md) | [50.3](/filings/0001600620-26-000017.md) | [57.2](/filings/0001600620-26-000017.md) | [67.8](/filings/0001600620-26-000017.md) | [59.9](/filings/0001600620-26-000017.md) | [62.5](/filings/0001600620-26-000049.md) | [70.0](/filings/0001600620-26-000062.md) | [73.5](/filings/0001600620-26-000017.md) | [77.1](/filings/0001600620-26-000017.md) | [77.7](/filings/0001600620-26-000049.md) | [83.2](/filings/0001600620-26-000062.md) |
| Cost of revenue | $m | [6.8](/filings/0001600620-24-000108.md) | [5.4 d](/filings/0001600620-26-000017.md) | [7.8](/filings/0001600620-25-000049.md) | [8.9](/filings/0001600620-25-000092.md) | [6.0](/filings/0001600620-25-000106.md) | [5.6 d](/filings/0001600620-26-000017.md) | [8.6](/filings/0001600620-26-000049.md) | [7.1](/filings/0001600620-26-000062.md) | [8.2](/filings/0001600620-25-000106.md) | [8.8 d](/filings/0001600620-26-000017.md) | [6.5](/filings/0001600620-26-000049.md) | [6.6](/filings/0001600620-26-000062.md) |
| Research and development | $m | [13.6](/filings/0001600620-24-000108.md) | [10.2 d](/filings/0001600620-26-000017.md) | [5.6](/filings/0001600620-25-000049.md) | [4.1](/filings/0001600620-25-000092.md) | [3.0](/filings/0001600620-25-000106.md) | [8.1 d](/filings/0001600620-26-000017.md) | [5.7](/filings/0001600620-26-000049.md) | [7.4](/filings/0001600620-26-000062.md) | [8.4](/filings/0001600620-25-000106.md) | [10.9 d](/filings/0001600620-26-000017.md) | [7.5](/filings/0001600620-26-000049.md) | [13.1](/filings/0001600620-26-000062.md) |
| Operating income | $m | [(16.3)](/filings/0001600620-25-000011.md) | [(29.7)](/filings/0001600620-25-000011.md) | [(13.3)](/filings/0001600620-26-000017.md) | [(1.5)](/filings/0001600620-26-000017.md) | [11.7](/filings/0001600620-26-000017.md) | [(1.7)](/filings/0001600620-26-000017.md) | [21.8](/filings/0001600620-26-000049.md) | [20.1](/filings/0001600620-26-000062.md) | [29.7](/filings/0001600620-26-000017.md) | [33.2](/filings/0001600620-26-000017.md) | [41.4](/filings/0001600620-26-000049.md) | [46.3](/filings/0001600620-26-000062.md) |
| Interest expense | $m | [1.4](/filings/0001600620-23-000044.md) | [1.3 d](/filings/0001600620-24-000012.md) | [1.3](/filings/0001600620-24-000051.md) | [1.2](/filings/0001600620-24-000091.md) | [1.2](/filings/0001600620-25-000106.md) | [1.1 d](/filings/0001600620-26-000017.md) | [1.1](/filings/0001600620-26-000049.md) | [1.1](/filings/0001600620-26-000062.md) | [1.1](/filings/0001600620-25-000106.md) | [1.0 d](/filings/0001600620-26-000017.md) | [1.0](/filings/0001600620-26-000049.md) | [0.9](/filings/0001600620-26-000062.md) |
| Income tax | $m | [0.3](/filings/0001600620-24-000108.md) | [0.5 d](/filings/0001600620-26-000017.md) | [0.7](/filings/0001600620-25-000049.md) | [0.8](/filings/0001600620-25-000092.md) | [0.5](/filings/0001600620-25-000106.md) | [(0.3) d](/filings/0001600620-26-000017.md) | [1.0](/filings/0001600620-26-000049.md) | [0.6](/filings/0001600620-26-000062.md) | [0.4](/filings/0001600620-25-000106.md) | [(175) d](/filings/0001600620-26-000017.md) | [9.6](/filings/0001600620-26-000049.md) | [11.4](/filings/0001600620-26-000062.md) |
| Net income | $m | [(13.4)](/filings/0001600620-25-000011.md) | [(26.9)](/filings/0001600620-25-000011.md) | [(10.7)](/filings/0001600620-26-000017.md) | [0.7](/filings/0001600620-26-000017.md) | [14.4](/filings/0001600620-26-000017.md) | [1.4](/filings/0001600620-26-000017.md) | [23.3](/filings/0001600620-26-000062.md) | [21.5](/filings/0001600620-26-000062.md) | [31.6](/filings/0001600620-26-000017.md) | [211](/filings/0001600620-26-000017.md) | [34.4](/filings/0001600620-26-000062.md) | [37.4](/filings/0001600620-26-000062.md) |
| Diluted EPS | $ per share | [(0.09)](/filings/0001600620-25-000011.md) | [(0.19)](/filings/0001600620-25-000011.md) | [(0.07)](/filings/0001600620-26-000017.md) | [0.01](/filings/0001600620-26-000017.md) | [0.10](/filings/0001600620-26-000017.md) | [0.01](/filings/0001600620-26-000017.md) | [0.16](/filings/0001600620-26-000049.md) | [0.16](/filings/0001600620-26-000062.md) | [0.23](/filings/0001600620-26-000017.md) | [1.53](/filings/0001600620-26-000017.md) | [0.25](/filings/0001600620-26-000049.md) | [0.28](/filings/0001600620-26-000062.md) |
| Basic EPS | $ per share | [(0.09)](/filings/0001600620-25-000011.md) | [(0.19)](/filings/0001600620-25-000011.md) | [(0.07)](/filings/0001600620-26-000017.md) | [0.01](/filings/0001600620-26-000017.md) | [0.10](/filings/0001600620-26-000017.md) | [0.01](/filings/0001600620-26-000017.md) | [0.17](/filings/0001600620-26-000049.md) | [0.16](/filings/0001600620-26-000062.md) | [0.24](/filings/0001600620-26-000017.md) | [1.60](/filings/0001600620-26-000017.md) | [0.26](/filings/0001600620-26-000049.md) | [0.29](/filings/0001600620-26-000062.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [45.6](/filings/0001600620-24-000108.md) | [48.8](/filings/0001600620-26-000017.md) | [63.9](/filings/0001600620-25-000049.md) | [33.3](/filings/0001600620-25-000092.md) | [36.6](/filings/0001600620-25-000106.md) | [83.4](/filings/0001600620-26-000017.md) | [66.1](/filings/0001600620-26-000049.md) | [52.9](/filings/0001600620-26-000062.md) | [72.9](/filings/0001600620-25-000106.md) | [80.2](/filings/0001600620-26-000017.md) | [40.7](/filings/0001600620-26-000049.md) | [180](/filings/0001600620-26-000062.md) |
| Current assets | $m | [426](/filings/0001600620-23-000044.md) | [425](/filings/0001600620-25-000011.md) | [398](/filings/0001600620-24-000051.md) | [410](/filings/0001600620-24-000091.md) | [440](/filings/0001600620-24-000108.md) | [447](/filings/0001600620-26-000017.md) | [406](/filings/0001600620-25-000049.md) | [409](/filings/0001600620-25-000092.md) | [439](/filings/0001600620-25-000106.md) | [492](/filings/0001600620-26-000062.md) | [480](/filings/0001600620-26-000049.md) | [541](/filings/0001600620-26-000062.md) |
| Total assets | $m | [555](/filings/0001600620-23-000044.md) | [548](/filings/0001600620-25-000011.md) | [517](/filings/0001600620-24-000051.md) | [524](/filings/0001600620-24-000091.md) | [549](/filings/0001600620-24-000108.md) | [551](/filings/0001600620-26-000017.md) | [505](/filings/0001600620-25-000049.md) | [503](/filings/0001600620-25-000092.md) | [528](/filings/0001600620-25-000106.md) | [752](/filings/0001600620-26-000062.md) | [724](/filings/0001600620-26-000049.md) | [792](/filings/0001600620-26-000062.md) |
| Current liabilities | $m | [73.9](/filings/0001600620-23-000044.md) | [77.2](/filings/0001600620-25-000011.md) | [71.1](/filings/0001600620-24-000051.md) | [76.9](/filings/0001600620-24-000091.md) | [78.6](/filings/0001600620-24-000108.md) | [97.8](/filings/0001600620-26-000017.md) | [68.4](/filings/0001600620-25-000049.md) | [78.3](/filings/0001600620-25-000092.md) | [76.2](/filings/0001600620-25-000106.md) | [93.7](/filings/0001600620-26-000062.md) | [86.6](/filings/0001600620-26-000049.md) | [99.9](/filings/0001600620-26-000062.md) |
| Total liabilities | $m | [163](/filings/0001600620-23-000044.md) | [170](/filings/0001600620-25-000011.md) | [157](/filings/0001600620-24-000051.md) | [159](/filings/0001600620-24-000091.md) | [161](/filings/0001600620-24-000108.md) | [173](/filings/0001600620-26-000017.md) | [155](/filings/0001600620-25-000049.md) | [167](/filings/0001600620-25-000092.md) | [162](/filings/0001600620-25-000106.md) | [170](/filings/0001600620-26-000062.md) | [156](/filings/0001600620-26-000049.md) | [177](/filings/0001600620-26-000062.md) |
| Shareholders' equity | $m | [392](/filings/0001600620-24-000108.md) | [378](/filings/0001600620-26-000017.md) | [359](/filings/0001600620-25-000106.md) | [365](/filings/0001600620-25-000106.md) | [388](/filings/0001600620-25-000106.md) | [377](/filings/0001600620-26-000062.md) | [350](/filings/0001600620-26-000062.md) | [335](/filings/0001600620-26-000062.md) | [366](/filings/0001600620-25-000106.md) | [581](/filings/0001600620-26-000062.md) | [568](/filings/0001600620-26-000062.md) | [615](/filings/0001600620-26-000062.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.3) d](/filings/0001600620-24-000108.md) | [14.3 d](/filings/0001600620-26-000017.md) | [(18.6)](/filings/0001600620-25-000049.md) | [15.8 d](/filings/0001600620-25-000092.md) | [17.0 d](/filings/0001600620-25-000106.md) | [30.1 d](/filings/0001600620-26-000017.md) | [1.3](/filings/0001600620-26-000049.md) | [44.2 d](/filings/0001600620-26-000062.md) | [44.4 d](/filings/0001600620-25-000106.md) | [45.7 d](/filings/0001600620-26-000017.md) | [32.6](/filings/0001600620-26-000049.md) | [52.6 d](/filings/0001600620-26-000062.md) |
| Share repurchases | $m | [0.0 d](/filings/0001600620-24-000108.md) | [0.0 d](/filings/0001600620-26-000017.md) | [12.3](/filings/0001600620-25-000049.md) | [6.1 d](/filings/0001600620-25-000092.md) | [0.0 d](/filings/0001600620-25-000106.md) | [21.8 d](/filings/0001600620-26-000017.md) | [46.9](/filings/0001600620-26-000049.md) | [42.6 d](/filings/0001600620-26-000062.md) | [8.7 d](/filings/0001600620-25-000106.md) | [0.0 d](/filings/0001600620-26-000017.md) | [36.2](/filings/0001600620-26-000049.md) | [38.7 d](/filings/0001600620-26-000062.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [142](/filings/0001600620-23-000044.md) | [143](/filings/0001600620-24-000051.md) | [143](/filings/0001600620-24-000091.md) | [143](/filings/0001600620-24-000108.md) | [144](/filings/0001600620-25-000049.md) | [144](/filings/0001600620-25-000092.md) | [146](/filings/0001600620-25-000106.md) | [143](/filings/0001600620-26-000049.md) | [138](/filings/0001600620-26-000062.md) | [136](/filings/0001600620-25-000106.md) | [138](/filings/0001600620-26-000049.md) | [134](/filings/0001600620-26-000062.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 133,051,168 at 2026-08-05, from the cover of the [10-Q filed 2026-08-06](/filings/0001600620-26-000062.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.